Cidara Therapeutics, Inc. (CDTX)
CDTX moved a median of +0.06% 30 minutes after news, and +0.09% by the close. How CDTX actually reacts to news — the realized, point-in-time move the market made, measured across 339 labeled events over the last three years with zero look-ahead.
CDTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 270 |
| 30-min | +0.06% | 52% | 290 |
| 60-min | +0.10% | 55% | 292 |
| to close | +0.09% | 52% | 291 |
| Middle 50% of CDTX reactions | -1.88% to +1.62% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 339 |
Half of all Cidara Therapeutics, Inc. news events land between -1.88% and +1.62% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CDTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 17 | +0.03% | 59% | +0.05% |
| Coverage initiations | 17 | -1.73% | 35% | -0.93% |
| Rating reiterations | 81 | -0.17% | 40% | +0.29% |
| Price-target raises | 21 | +0.16% | 57% | +2.36% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how CDTX ranks against every other measured name →
That’s how CDTX usually reacts — get an email when it moves on news →Email me when CDTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CDTX's baseline. Nothing else.
Recent CDTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Cidara Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Cidara Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Cidara Therapeutics, For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Cidara Therapeutics, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Cidara Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | +0.01% | +0.11% | |
| Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | -0.03% | +0.06% | |
| Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations | Press release | GlobeNewswire | -0.06% | +0.30% | |
| Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | +0.00% | -0.12% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI) | Press release | GlobeNewswire | +0.25% | -0.24% | |
| CDTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Cidara Therapeutics, Inc. is Fair to Shareholders | Press release | Business Wire | +0.21% | +0.14% | |
| Form 8-K Cidara Therapeutics, For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.21% | +0.14% | |
| Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | -0.04% | -0.02% | |
| Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +4.75% | +6.21% | |
| Form 10-Q Cidara Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.75% | +6.21% | |
| Form 8-K Cidara Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +4.75% | +6.21% | |
| Cidara Therapeutics to Participate in November Investor Conferences | Press release | GlobeNewswire | -0.12% | +5.36% | |
| Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10?? ESWI Influenza Conference 2025 | Press release | GlobeNewswire | -0.92% | -3.11% | |
| Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025 | Press release | GlobeNewswire | -0.25% | -4.73% | |
| Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 | Press release | GlobeNewswire | -0.12% | +3.86% | |
| Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 | Press release | GlobeNewswire | -0.26% | +2.76% | |
| Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 | Press release | GlobeNewswire | +2.43% | -2.88% | |
| Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention | Press release | GlobeNewswire | +0.34% | +8.59% | |
| Form 8-K Cidara Therapeutics, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -6.89% | |
| Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic | Press release | GlobeNewswire | -0.81% | +2.18% | |
| Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations | Press release | GlobeNewswire | +0.72% | +7.02% | |
| Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza | Press release | GlobeNewswire | +4.07% | +14.44% | |
| Form 8-K Cidara Therapeutics, For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +4.07% | +14.44% | |
| Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting | Press release | GlobeNewswire | +0.77% | +0.20% | |
| Cidara Therapeutics to Participate in September Investor Conferences | Press release | GlobeNewswire | +0.95% | +3.10% | |
| Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting | Press release | GlobeNewswire | -0.06% | -0.44% | |
| Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +4.71% | +7.29% | |
| Form 10-Q Cidara Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.71% | +7.29% | |
| Form 8-K Cidara Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +4.71% | +7.29% | |
| Form S-8 Cidara Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +4.71% | +7.29% | |
| Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 | Press release | GlobeNewswire | -2.21% | -2.33% | |
| Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | GlobeNewswire | -2.08% | +0.57% | |
| Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes | Press release | GlobeNewswire | +0.58% | +0.43% | |
| Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +0.69% | +5.78% | |
| Form 8-K Cidara Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +1.74% | -1.82% | |
| Cidara Announces Pricing of Upsized Public Offering of Common Stock | Press release | GlobeNewswire | +5.86% | +12.94% | |
| Form 8-K Cidara Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +5.86% | +12.94% | |
| Cidara Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | +4.96% | -5.77% | |
| Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza | Press release | GlobeNewswire | -0.66% | +10.14% | |
| Form 8-K Cidara Therapeutics, For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | +10.14% | |
| Form 8-K Cidara Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | +10.14% | |
| Form EFFECT Cidara Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +18.49% | |
| Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 | Press release | GlobeNewswire | +0.65% | +8.85% | |
| Cidara Therapeutics to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | -0.13% | -2.52% | |
| Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | Press release | GlobeNewswire | -4.08% | -11.16% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CDTX section they belong to.
Where else CDTX is measured.
CDTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Brookdale Senior Living Inc. (BKD) | 341 | +0.36% | 62% |
| Vaxart, Inc. (VXRT) | 341 | -0.81% | 41% |
| DaVita Inc. (DVA) | 339 | +0.07% | 53% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 339 | +0.29% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cidara Therapeutics, Inc.'s median reaction calculated?
Every labeled CDTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 339 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of CDTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CDTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.